By Daniella Parra
Creyon Bio, Inc. and Cajal Neuroscience have teamed up to develop therapies for neurodegenerative diseases, they said.
The companies aim to accelerate the development of treatments for common neurodegenerative disorders, engineering medicines using human data and experimental capabilities, Creyon said.
“Using our human genetics platform we have identified novel targets that are well suited to oligonucleotide therapeutics,” said Ian Peikon, Ph.D., & Andrew Dervan, M.D., Co-Founders & Co-Chief Executive Officers of Cajal Neuroscience. “Creyon’s expertise in developing ASOs has been instrumental in our ability to prosecute on the targets we have identified.”
